Humoral immunity to smallpox vaccines and monkeypox virus challenge: Proteomic assessment and clinical correlations

Journal of Virology

Volumn 87, Issue 2, 2013, Pages 900-911

  Townsend, M B ^a   Keckler, M S ^a   Patel, N ^a   Davies, D H ^b,c   Felgner, P ^b,c   Damon, I K ^a   Karema, K L ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Antigen Discovery Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SMALLPOX VACCINE; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY REACTION; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL DOG; HUMAN; HUMORAL IMMUNITY; INFECTION PREVENTION; LOW DRUG DOSE; MONKEYPOX; NONHUMAN; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEOMICS; SMALLPOX; VACCINATION; VIRUS NEUTRALIZATION; VIRUS VIRULENCE;

ANIMALS; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HOST-PATHOGEN INTERACTIONS; HUMANS; MONKEYPOX VIRUS; NEUTRALIZATION TESTS; POXVIRIDAE INFECTIONS; PROTEIN ARRAY ANALYSIS; PROTEOME; SCIURIDAE; SMALLPOX VACCINE;

ANIMALIA; CYNOMYS; CYNOMYS LUDOVICIANUS; MONKEYPOX VIRUS; ORTHOPOXVIRUS; VARIOLA VIRUS;

EID: 84871985968     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02089-12     Document Type: Article

References (71)

1. Breman JG, Arita I. 1980. The confirmation and maintenance of smallpox eradication. N. Engl. J. Med. 303:1263-1273.
2. Chapman JL, Nichols DK, Martinez MJ, Raymond JW. 2010. Animal models of orthopoxvirus infection. Vet. Pathol. 47:852-870.
3. Trindade GS, Emerson GL, Carroll DS, Kroon EG, Damon IK. 2007. Brazilian vaccinia viruses and their origins. Emerg. Infect. Dis. 13:965-972.
4. Vorou RM, Papavassiliou VG, Pierroutsakos IN. 2008. Cowpox virus infection: an emerging health threat. Curr. Opin. Infect. Dis. 21:153-156.
5. Rimoin AW, Mulembakani PM, Johnston SC, Lloyd Smith JO, Kisalu NK, Kinkela TL, Blumberg S, Thomassen HA, Pike BL, Fair JN, Wolfe ND, Shongo RL, Graham BS, Formenty P, Okitolonda E, Hensley LE, Meyer H, Wright LL, Muyembe JJ. 2010. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc. Natl. Acad. Sci. U. S. A. 107:16262-16267.
6. Jacobs BL, Langland JO, Kibler KV, Denzler KL, White SD, Holechek SA, Wong S, Huynh T, Baskin CR. 2009. Vaccinia virus vaccines: past, present and future. Antivir. Res. 84:1-13.
7. Centers for Disease Control and Prevention. 2003. Supplemental recommendations on adverse events following smallpox vaccine in the preevent vaccination program: recommendations of the Advisory Committee on Immunization Practices. JAMA 289:2064.
8. Cassimatis DC, Atwood JE, Engler RM, Linz PE, Grabenstein JD, Vernalis MN. 2004. Smallpox vaccination and myopericarditis: a clinical review. J. Am. Coll. Cardiol. 43:1503-1510.
9. Lane JM, Ruben FL, Neff JM, Millar JD. 1969. Complications of smallpox vaccination, 1968. N. Engl. J. Med. 281:1201-1208.
10. Monath TP, Caldwell JR, Mundt W, Fusco J, Johnson CS, Buller M, Liu J, Gardner B, Downing G, Blum PS, Kemp T, Nichols R, Weltzin R. 2004. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)-a second-generation smallpox vaccine for biological defense. Int. J. Infect. Dis. 8(Suppl. 2):S31-S44.
11. Vollmar J, Arndtz N, Eckl KM, Thomsen T, Petzold B, Mateo L, Schlereth B, Handley A, King L, Hulsemann V, Tzatzaris M, Merkl K, Wulff N, Chaplin P. 2006. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 24:2065-2070.
12. Midgley CM, Putz MM, Weber JN, Smith GL. 2008. Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax. J. Gen. Virol. 89:2992-2997.
13. Edghill-Smith Y, Bray M, Whitehouse CA, Miller D, Mucker E, Manischewitz J, King LR, Robert-Guroff M, Hryniewicz A, Venzon D, Meseda C, Weir J, Nalca A, Livingston V, Wells J, Lewis MG, Huggins J, Zwiers SH, Golding H, Franchini G. 2005. Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge. J. Infect. Dis. 191:372-381.
14. Grandpre LE, Duke-Cohan JS, Ewald BA, Devoy C, Barouch DH, Letvin NL, Reinherz EL, Baden LR, Dolin R, Seaman MS. 2009. Immunogenicity of recombinant modified vaccinia ankara following a single or multi-dose vaccine regimen in rhesus monkeys. Vaccine 27:1549-1556.
15. Riedmann EM. May 2010. FDA Fast Track status for IMVAMUNE. Hum. Vaccin. 6:368-372. http://dx.doi.org/10.4161/hv.6.5.12214.
16. Jahrling PB, Hensley LE, Martinez MJ, Leduc JW, Rubins KH, Relman DA, Huggins JW. 2004. Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc. Natl. Acad. Sci. U. S. A. 101:15196-15200.
17. Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH, Eisenberg RJ, Hartmann CJ, Jackson DL, Kulesh DA, Martinez MJ, Miller DM, Mucker EM, Shamblin JD, Zwiers SH, Huggins JW, Jahrling PB, Moss B. 2004. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428:182-185.
18. Zaucha GM, Jahrling PB, Geisbert TW, Swearengen JR, Hensley L. 2001. The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab. Invest. 81:1581-1600.
19. Karupiah G, Buller RM, Van Rooijen N, Duarte CJ, Chen J. 1996. Different roles for CD4+ and CD8+ T lymphocytes and macrophage subsets in the control of a generalized virus infection. J. Virol. 70:8301-8309.
20. Martinez MJ, Bray MP, Huggins JW. 2000. A mouse model of aerosoltransmitted orthopoxviral disease: morphology of experimental aerosoltransmitted orthopoxviral disease in a cowpox virus-BALB/c mouse system. Arch. Pathol. Lab. Med. 124:362-377.
21. Schriewer J, Buller RM, Owens G. 2004. Mouse models for studying orthopoxvirus respiratory infections. Methods Mol. Biol. 269:289-308.
22. Adams MM, Rice AD, Moyer RW. 2007. Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox. J. Virol. 81: 11084-11095.
23. Reed KD, Melski JW, Graham MB, Regnery RL, Sotir MJ, Wegner MV, Kazmierczak JJ, Stratman EJ, Li Y, Fairley JA, Swain GR, Olson VA, Sargent EK, Kehl SC, Frace MA, Kline R, Foldy SL, Davis JP, Damon IK. 2004. The detection of monkeypox in humans in the Western Hemisphere. N. Engl. J. Med. 350:342-350.
24. Hutson CL, Olson VA, Carroll DS, Abel JA, Hughes CM, Braden ZH, Weiss S, Self J, Osorio JE, Hudson PN, Dillon M, Karem KL, Damon IK, Regnery RL. 2009. A prairie dog animal model of systemic orthopoxvirus disease using West African and Congo Basin strains of monkeypox virus. J. Gen. Virol. 90:323-333.
25. Keckler MS, Carroll DS, Gallardo-Romero NF, Lash RR, Salzer JS, Weiss SL, Patel N, Clemmons CJ, Smith SK, Hutson CL, Karem KL, Damon IK. 2011. Establishment of the black-tailed prairie dog (Cynomys ludovicianus) as a novel animal model for comparing smallpox vaccines administered preexposure in both high- and low-dose monkeypox virus challenges. J. Virol. 85:7683-7698.
26. Belyakov IM, Earl P, Dzutsev A, Kuznetsov VA, Lemon M, Wyatt LS, Snyder JT, Ahlers JD, Franchini G, Moss B, Berzofsky JA. 2003. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl. Acad. Sci. U. S. A. 100:9458-9463.
27. Liu L, Zhong Q, Tian T, Dubin K, Athale SK, Kupper TS. 2010. Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity. Nat. Med. 16:224-227.
28. Panchanathan V, Chaudhri G, Karupiah G. 2008. Correlates of protective immunity in poxvirus infection: where does antibody stand? Immunol. Cell Biol. 86:80-86.
29. Panchanathan V, Chaudhri G, Karupiah G. 2006. Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function. J. Virol. 80:6333-6338.
30. Edghill-Smith Y, Golding H, Manischewitz J, King LR, Scott D, Bray M, Nalca A, Hooper JW, Whitehouse CA, Schmitz JE, Reimann KA, Franchini G. 2005. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat. Med. 11:740-747.
31. Davies DH, McCausland MM, Valdez C, Huynh D, Hernandez JE, Mu Y, Hirst S, Villarreal L, Felgner PL, Crotty S. 2005. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J. Virol. 79:11724-11733.
32. Fogg CN, Americo JL, Earl PL, Resch W, Aldaz-Carroll L, Eisenberg RJ, Cohen GH, Moss B. 2008. Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge. J. Virol. 82:8022-8029.
33. Heraud JM, Edghill-Smith Y, Ayala V, Kalisz I, Parrino J, Kalyanaraman VS, Manischewitz J, King LR, Hryniewicz A, Trindade CJ, Hassett M, Tsai WP, Venzon D, Nalca A, Vaccari M, Silvera P, Bray M, Graham BS, Golding H, Hooper JW, Franchini G. 2006. Subunit recombinant vaccine protects against monkeypox. J. Immunol. 177:2552-2564.
34. Hooper JW, Ferro AM, Golden JW, Silvera P, Dudek J, Alterson K, Custer M, Rivers B, Morris J, Owens G, Smith JF, Kamrud KI. 2009. Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates. Vaccine 28:494-511.
35. Kaufman DR, Goudsmit J, Holterman L, Ewald BA, Denholtz M, Devoy C, Giri A, Grandpre LE, Heraud JM, Franchini G, Seaman MS, Havenga MJ, Barouch DH. 2008. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice. J. Virol. 82:6829-6837.
36. Shinoda K, Wyatt LS, Moss B. 2010. The neutralizing antibody response to the vaccinia virus A28 protein is specifically enhanced by its association with the H2 protein. Virology 405:41-49.
37. Wallengren K, Risco C, Krijnse-Locker J, Esteban M, Rodriguez D. 2001. The A17L gene product of vaccinia virus is exposed on the surface of IMV. Virology 290:143-152.
38. Xu C, Meng X, Yan B, Crotty S, Deng J, Xiang Y. 2011. An epitope conserved in orthopoxvirus A13 envelope protein is the target of neutralizing and protective antibodies. Virology 418:67-73.
39. Benhnia MR, McCausland MM, Su HP, Singh K, Hoffmann J, Davies DH, Felgner PL, Head S, Sette A, Garboczi DN, Crotty S. 2008. Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine. J. Virol. 82:3751-3768.
40. Davies DH, Molina DM, Wrammert J, Miller J, Hirst S, Mu Y, Pablo J, Unal B, Nakajima-Sasaki R, Liang X, Crotty S, Karem KL, Damon IK, Ahmed R, Villarreal L, Felgner PL. 2007. Proteome-wide analysis of the serological response to vaccinia and smallpox. Proteomics 7:1678-1686.
41. Duke-Cohan JS, Wollenick K, Witten EA, Seaman MS, Baden LR, Dolin R, Reinherz EL. 2009. The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays. Vaccine 27:1154-1165.
42. Schmid K, Keasey SL, Pittman P, Emerson GL, Meegan J, Tikhonov AP, Chen GX, Schweitzer B, Ulrich RG. 2008. Analysis of the human immune response to vaccinia by use of a novel protein microarray suggests that antibodies recognize less than 10% of the total viral proteome. Proteomics Clin. Appl. 2:1528-1538.
43. Flesch IE, Woo WP, Wang Y, Panchanathan V, Wong YC, La Gruta NL, Cukalac T, Tscharke DC. 2010. Altered CD8(+) T cell immunodominance after vaccinia virus infection and the naive repertoire in inbred and F(1) mice. J. Immunol. 184:45-55.
44. Davies DH, Wyatt LS, Newman FK, Earl PL, Chun S, Hernandez JE, Molina DM, Hirst S, Moss B, Frey SE, Felgner PL. 2008. Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus Ankara is comparable to that of Dryvax. J. Virol. 82:652-663.
45. Davies DH, Liang X, Hernandez JE, Randall A, Hirst S, Mu Y, Romero KM, Nguyen TT, Kalantari-Dehaghi M, Crotty S, Baldi P, Villarreal LP, Felgner PL. 2005. Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc. Natl. Acad. Sci. U. S. A. 102:547-552.
46. Keckler MS, Gallardo-Romero NF, Langham GL, Damon IK, Karem KL, Carroll DS. 2010. Physiologic reference ranges for captive blacktailed prairie dogs (Cynomys ludovicianus). J. Am. Assoc. Lab. Anim. Sci. 49:274-281.
47. Cangene. 2005. Highlights of prescribing information: CNJ-016, vaccinia immune globulin intravenous (human). Cangene, Winnipeg, Canada.
48. Karem KL, Reynolds M, Braden Z, Lou G, Bernard N, Patton J, Damon IK. 2005. characterization of acute-phase humoral immunity to monkeypox: use of immunoglobulinMenzyme-linked immunosorbent assay for detection of monkeypox infection during the 2003 North American outbreak. Clin. Diagn. Lab. Immunol. 12:867-872.
49. Johnson MC, Damon IK, Karem KL. 2008. A rapid, high-throughput vaccinia virus neutralization assay for testing smallpox vaccine efficacy based on detection of green fluorescent protein. J. Virol. Methods 150:14-20.
50. Lawrence SJ, Lottenbach KR, Newman FK, Buller RML, Bellone CJ, Chen JJ, Cohen GH, Eisenberg RJ, Belshe RB, Stanley SL, Frey SE. 2007. Antibody responses to vaccinia membrane proteins after smallpox vaccination. J. Infect. Dis. 196:220-229.
51. Wolffe EJ, Moore DM, Peters PJ, Moss B. 1996. Vaccinia virus A17L open reading frame encodes an essential component of nascent viral membranes that is required to initiate morphogenesis. J. Virol. 70:2797-2808.
52. Kochan G, Escors D, Gonzalez JM, Casasnovas JM, Esteban M. 2008. Membrane cell fusion activity of the vaccinia virus A17-A27 protein complex. Cell Microbiol. 10:149-164.
53. Sakhatskyy P, Wang S, Zhang C, Chou TH, Kishko M, Lu S. 2008. Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens. Virology 371:98-107.
54. Wolffe EJ, Vijaya S, Moss B. 1995. A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies. Virology 211:53-63.
55. Payne LG, Kristensson K. 1985. Extracellular release of enveloped vaccinia virus from mouse nasal epithelial cells in vivo. J. Gen. Virol. 66:643-646.
56. Putz MM, Midgley CM, Law M, Smith GL. 2006. Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination. Nat. Med. 12:1310-1315.
57. Chung CS, Chen CH, Ho MY, Huang CY, Liao CL, Chang W. 2006. Vaccinia virus proteome: identification of proteins in vaccinia virus intracellular mature virion particles. J. Virol. 80:2127-2140.
58. Resch W, Hixson KK, Moore RJ, Lipton MS, Moss B. 2007. Protein composition of the vaccinia virus mature virion. Virology 358:233-247.
59. Keasey S, Pugh C, Tikhonov A, Chen G, Schweitzer B, Nalca A, Ulrich RG. 2010. Proteomic basis of the antibody response to monkeypox virus infection examined in cynomolgus macaques and a comparison to human smallpox vaccination. PLoS One 5:e15547. doi:10.1371/journal. pone.0015547.
60. Sodeik B, Griffiths G, Ericsson M, Moss B, Doms RW. 1994. Assembly of vaccinia virus: effects of rifampin on the intracellular distribution of viral protein p65. J. Virol. 68:1103-1114.
61. Condit RC, Moussatche N, Traktman P. 2006. In a nutshell: structure and assembly of the vaccinia virion. Adv. Virus Res. 66:31-124.
62. Handley L, Buller RM, Frey SE, Bellone C, Parker S. 2009. The new ACAM2000 vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks. Expert Rev. Vaccines 8:841-850.
63. Hermanson G, Chun S, Felgner J, Tan X, Pablo J, Nakajima-Sasaki R, Molina DM, Felgner PL, Liang X, Davies DH. 2012. Measurement of antibody responses to modified vaccinia virus Ankara (MVA) and Dryvax((R)) using proteome microarrays and development of recombinant protein ELISAs. Vaccine 30:614-625.
64. Assarsson E, Greenbaum JA, Sundstrom M, Schaffer L, Hammond JA, Pasquetto V, Oseroff C, Hendrickson RC, Lefkowitz EJ, Tscharke DC, Sidney J, Grey HM, Head SR, Peters B, Sette A. 2008. Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes. Proc. Natl. Acad. Sci. U. S. A. 105:2140-2145.
65. Broyles SS. 2003. Vaccinia virus transcription. J. Gen. Virol. 84:2293-2303.
66. Yang Z, Reynolds SE, Martens CA, Bruno DP, Porcella SF, Moss B. 2011. Expression profiling of the intermediate and late stages of poxvirus replication. J. Virol. 85:9899-9908.
67. Colamonici OR, Domanski P, Sweitzer SM, Larner A, Buller RM. 1995. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J. Biol. Chem. 270: 15974-15978.
68. Hooper JW, Custer DM, Thompson E. 2003. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 306:181-195.
69. Hughes CM, Newman FK, Davidson WB, Olson VA, Smith SK, Holman RC, Yan L, Frey SE, Belshe RB, Karem KL, Damon IK. 2012. Analysis of variola and vaccinia virus neutralization assays for smallpox vaccines. Clin. Vaccine Immunol. 19:1116-1118.
70. Hammarlund E, Lewis MW, Hanifin JM, Mori M, Koudelka CW, Slifka MK. 2010. Antiviral immunity following smallpox virus infection: a casecontrol study. J. Virol. 84:12754-12760.
71. Karem KL, Reynolds M, Hughes C, Braden Z, Nigam P, Crotty S, Glidewell J, Ahmed R, Amara R, Damon IK. 2007. Monkeypox-induced immunity and failure of childhood smallpox vaccination to provide complete protection. Clin. Vaccine Immunol. 14:1318-1327.